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Abstract: Th e prevalence of vitamin D defi ciency in the American and European population is estimated 
to be extremely high. Although fewer people today suff er from serious health problems related to calcium 
and phosphate metabolism resulting from vitamin D defi ciency, there are more and more studies sug-
gesting that calcitriol may play an important role in the pathogenesis of other diseases in virtually every 
body system. A growing body of research shows that through its ubiquitously expressed receptor, calcitriol 
displays potent anti-angiogenic an anti-infl ammatory activity. Th is review summarizes recent discoveries 
regarding these non-classical eff ects of vitamin D and their clinical implications. Data collection focused 
on the prevention and treatment of ocular diseases as well as on the underlying mechanisms.
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Background/introduction
Vitamin D is typically associated with calcium and phosphate metabolism but, since its 
fi rst identifi cation, there has been a number of publications reporting the involvement 
of vitamin D in a  myriad of new functions. Th e  growing interest in this substance 
has started with the discovery of the vitamin D receptor (VDR), its DNA-binding 
capabilities and vitamin D response elements (VDREs) — specifi c DNA binding 
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sites [1].  Current studies show that the active vitamin D metabolite (1α,25(OH)2D3) 
recognizes VDREs and alter DNA transcription. All of these actions are mediated by 
vitamin D receptors, heterodimerized with retinoic X receptors, which bind to the 
regulatory sites in target genes. Apart from at least eleven genes involved in bone 
and mineral homeostasis [2],  VDRs and 1-hydroxylase enzyme have been discovered 
in multiple diff erent tissues where 1,25(OH)D infl uences locally the transcriptional 
output. It has been proven that vitamin D interacts directly with 0.8–5% of the total 
genome [3]. Th ese new fi ndings revealed that vitamin D controls multiple of biological 
processes including cellular growth, angiogenesis or even modulation of immune 
[4] and cardiovascular system [5], diff  erentiation of keratinocytes [6], inhib ition of 
proliferation of breast [7], colon  [8] and pros tate cancer cells [9]. Th e  non-s keletal 
eff ects explain the wide variety of pathologic conditions that have been linked to 
vitamin D insuffi  ciency.
Th e vitamin D metabolism pathway
Vitamin D can be either produced in the skin through two-step non-enzymatic 
process or obtained from the diet in a  form of two biologically inactive precursors. 
Th e  dietary sources include ergocalciferol (D2) from plants and cholecalciferol 
(D3) mostly from marine life. Both alimentary forms undergo the same activation 
pathways and their fi nal eff ect/biological action on cells is almost equivalent. 
Nevertheless, the keratinocytes of the skin are the primary source of vitamin D for the 
body [6].
Sunlight-m ediated photolysis of cutaneous 7-dehydrocholesterol begins when 
the epidermis is exposed, for a  suffi  cient amount of time, to ultraviolet B radiation 
(280–320 nm). Irradiation of 7-DHC breaks the ring of precursor sterol to form 
pre-D3 and then, due to temperature dependent rearrangement, it is converted to 
actual D3 (Fig. 1).
Before vitamin D becomes the active hormone (1α,25(OH)2D3), it undergoes 
metabolic activation by hydroxylases — forms of cytochrome P450. Th e fi rst step is 
conducted mostly in the liver by CYP2R1 resulting in 25-hydroxylated vitamin D. 
Moreover, there is some research indicating that other hydroxylases may be involved 
such as mitochondrial CYP27A1 or microsomal CYP2D11, CYP2D25, CYP2J2/3, and 
CYP3A4. Th e  synthesis of 25(OH)D also occur, to some extent, locally because of 
the expression of CYP2R1 in many tissues [10]. It may be the re ason why in patients 
with liver failure vitamin-D production is maintained. Even so, the hepatic CYP2R1 
remains the main site of its 25-hydroxylation in a healthy body. 
In the circulation, 25(OH)D is bound to vitamin D binding protein(DBP). In 
order for the next hydroxylation to take place, complexes of 25(OH)D and DBP need 
to be reabsorbed from the glomerular fi ltrate at the proximal tubule of the kidney. 
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Th is uptake DBP is facilitated by endocytic receptor — megalin in conjunction with 
cubilin [11]. Th en, lysosomal enzymes inside the cell degrade DBP, making 25(OH)D 
available for further enzymatic modifi cations. In clinical practice, both free and total 
serum level of 25(OH)D is used to assess vitamin D status. It has signifi cantly longer 
half-life and reaches higher plasma concentrations than 1,25(OH)2D.
Fig. 1. Vitamin D production.
Th e further enzymatic process occurs in the kidney where 25(OH)D is hydroxylated 
into the biologically active 1,25-dihydroxyvitamin D. Th is metabolite has the highest 
affi  nity for the nuclear VDR, thereby making it the most active form of vitamin D. 
Th e second hydroxylation is catalyzed by the mitochondrial enzyme CYP27B1. Its renal 
activity is crucial for maintaining the optimal level of circulating 1,25(OH)D, although 
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1-hydroxylase is expressed widely in non-renal cells as well. Regarding the extra-renal 
CYP27B1 expression, of particular signifi cance are disease-activated macrophages and 
placenta which are the only sites, so far as is known, capable of providing enough 
hormone to raise the serum level of vitamin D [12].
24-hydroxylase e nzyme (CYP24A1 gene) is responsible for the ensuing step in 
vitamin D metabolism. This enzyme inactivates both 25(OH)D and 1,25(OH)2D 
through its multi-catalytic activity. It can be induced by 1,25(OH)2D, and hence 
auto-regulates its circulating concentration. As a result, CYP24A1 defects may cause 
severe hypercalcemia [13]. 
In addition, the re are reports suggesting that the product of this inactivation 
24,25(OH)2D has signifi cant activity, and infl uences processes such as cartilage and 
osteoblasts maturation [14, 15].
Regulation of plasma 1,25(OH)D concentration
Production of 1,25(OH)2D is tightly regulated by the action of specifi c hormones 
on the expression of CYP27B1 and CYP24. As mentioned above, the role of these 
genes is to, respectively, activate and inactivate vitamin D metabolites, and thus they 
maintain calcium and phosphate homeostasis.
In hypocalcemic state, parathyroid hormone(PTH) induces expression of 
CYP27B1 in the renal proximal tubular cells, thereby stimulating 1-hydroxylation 
of 25(OH)D. At the same time, PTH inhibits CYP24 — vitamin D inactivator. As 
a result, the production of 1,25(OH)2D increases, leading to a rise in the serum level 
of calcium.
On the contrary, fi broblast growth factor (FGF 23) suppress vitamin D hormone 
production in the kidney. FGF-23, which requires an obligatory co-receptor Klotho, 
is a  protein produced mostly by osteocytes and osteoblasts. Bony secretion of this 
hormone is stimulated by phosphate, PTH and 1,25(OH)2D [16]. Th ere is a negative 
feedback loop since it functions as a  down-regulator of renal 1-hydroxylation by 
suppression of CYP27B1. Additionally, both FGF23 and 1,25-dihydroxyvitamin D 
up-regulate CYP24 expression. 
As indicated earlier, 1,25(OH)2D is a strong activator of CYP24 gene transcription. 
But to fully understand vitamin D feedback circuit, it is important to mention that 
this hormone also suppresses CYP27B1 expression, as well as, PTH production and 
secretion. Moreover, it acts as the FGF23 stimulator. Several additional factors also 
regulate renal CYP27B1 activity including calcitonin, insulin, growth hormone and 
prolactin [17].
1,25-dihydroxyvitami n D acts as a  ligand for the vitamin D receptor in target 
cells. VDR is a  DNA-binding transcriptional factor, which in active (liganded) 
state, heterodimerizes with retinoic X receptor. Subsequently, the signal transducing 
 Th e role of vitamin D in the pathogenesis of ocular diseases 107
complex of 1,25(OH)2D, VDR and RXR is able to migrate into the nucleus where 
recognizes specifi c DNA sites and infl uences gene transcription. DNA sequences 
of vitamin-D regulated genes are called vitamin D response elements (VDRE). 
Aft er binding to the VDRE, heterodimer recruits complexes of co-regulators. Th ese 
various regulating proteins complexing to the liganded VDR-RXR determine the cell 
or tissue specifi city of the response. Th ey act as inductors or repressors of genomic 
activities through chromatin remodeling, histone modifi cations and recruiting RNA 
polymerase II [18].
Th ere is evidence tha t vitamin D activity includes also a number of rapid actions 
that usually last only a  short time. As the eff ect at the genome level needs hours to 
occur, these actions are considered to be “non-genomic”. However, VDR has been 
recognized to be necessary for this non-genomic pathway to function [19] and the 
fi nal result of m any of these non-transcriptional responses is, in fact, an alteration of 
gene output.
Th ese non-classical actions are recognized to be responsible for the regulation 
of transmembrane transport of calcium and chloride as well as stimulation of 
intracellular signaling pathways through triggering the activation of signaling 
molecules, the rapid generation of second messengers and the activation of protein 
kinases [20]. 1,25(OH)2D induce these ra pid actions through binding to the membrane 
receptors. Th e scientists identifi ed a  specifi c binding protein for 1,25(OH)2D named 
membrane-associated rapid response steroid (MARRS) [21]. The  protein is also 
known a s Pdia3, ERp60, ERp57 or Grp58. It is located within caveolae which are 
small, ‘cup-shaped’ invaginations of the plasma membrane.
On the other hand, it was demonstrated that 1,25(OH)2D can initiate rapid 
responses via the classic VDR, which is typically associated with traditional genomic 
responses. Th e  vitamin D receptor, which is normally found in the nucleus, is also 
present in caveolae-enriched plasma membranes [22]. It is suggested that these 
VDR- mediated rapid responses can be generated through binding of 1,25(OH)2D to 
an alternative ligand binding pocket [23].
Both Pdia3 and VDR are complexed to caveolin-1, the caveolae marker protein, 
which seems to be an essential scaff old to activate downstream mediators — diff erent 
for each of the receptors. The  Pdia3 binds phospholipase A2 activation protein 
(PLAA) while VDR is coupled to c-Src [24].
Eye-specifi c eff ects
Th e latest res earch on metabolism and action of vitamin D revealed that it acts more 
extensively than merely regulation of calcium and phosphate homeostasis. Due to 
VDR expression in non-classic tissues, 1,25(OH)2D displays local activity regulating 
many additional cell-specifi c biological processes. Using immunochemistry scientists 
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identifi ed VDR in the intestinal epithelium, renal tubules, parathyroid gland, 
keratinocytes, mammary epithelium, pancreas, pituitary gland, skeleton, immune 
system, and germ tissues [25]. Furthermore, vitamin D can be activat ed locally due to 
the extra-renal expression of CYP27B1 which has been discovered in a  wide variety 
of tissues including respiratory [26], prostate, colonic epithelial cells, as well as, 
osteoblasts and macrophages [27].
Most importantly, for this review, rece nt studies revealed the presence of VDR, 
along with 1-hydroxylase, in the eye [28]. RT-PCR of ocular cells has found strong 
 expression of VDR in primary human scleral fi broblasts, corneal endothelial cells, 
adult retinal pigment epithelial cells and non-pigmented ciliary body epithelial 
cells. Further examination of mRNA expression, combined with immunofl uorescent 
staining, detected in these cells, not only the receptor but also the enzymes required 
in vitamin D metabolism [29]. It may suggest that vitamin D function as a paracrine/
autocrine regulator. Th is hypothesis has recently been supported by experimental 
results. Cultures of retinal and corneal cells treated with 25(OH)D have demonstrated 
ability to convert it into active 1,25(OH)2D [29]. A separate study presented 25(OH)D 
synthes is in corneal limbal cells from exogenous 7-dehydrocholesterol aft er being 
exposed to the low doses of UV-B radiation [30]. Above-mentioned fi ndings indicate 
that vita min D may be produced locally following sunlight exposure.
Th e  research on VDR involves the retinal vasculature as well. It was shown that 
in retinal pericytes VDR is strongly expressed compared to endothelial cells and that 
calcitriol in vitro amplifi es the level of this expression [31].
Measurable concentrations of vitamin D metab olites have been also detected 
in tear fl uid as well as in aqueous and vitreous humor [30]. In addition, there is 
an evidence, obtained f rom a  mouse study, for the presence of megalin and cubilin 
in the lacrimal and Handerian glands which are responsible for the production 
of tear fluid  [32]. This complex of receptors, required for the in ternalization 
of 25(OH)D-DBP in kidneys, may also be involved in the process of vitamin D secre-
tion into tear fl uid. Moreover, chemiluminescent immunoassay allowed to measure 
the 25-hydroxyvitamin D concentrations in human tears and it was found to be even 
higher than corresponding serum levels of 25(OH)D [33].
In aqueous humor, calcitriol was not merely mea sured but also identified as 
potential factor able to modulate both aqueous humor production and outflow. 
Microarray analysis of rat and mouse DNA led to the discovery that 1,25(OH)2D 
induces changes in the expression of the genes involved in the regulation of intraocular 
pressure [34]. Following studies showed that topical administra tion of vitamin D 
analogs signifi cantly lower IOP in nonhuman primates [34]. However, changes in the 
aqueous humor formation o r outfl ow were not observed. 
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Eff ects of vitamin D on corneal function
Proper functioning of the cornea is necessary for good vision since it is an outer, 
transparent, protective layer of the eye that refracts light. Corneal cells express all 
the enzymes necessary for the metabolism of vitamin D therefore they are able to 
produce the active form of vitamin D from the non-hydroxylated metabolite  [35]. 
Local production suggests the local activity of ca lcitriol in the cornea. Studies 
involving vitamin D therapy have shown that it may aff ect the function of the corneal 
epithelium. Yin et al. reported that 1,25(OH)2D and 25(OH)D cause an increase in 
transepithelial resistance in human corneal epithelial cells which refl ects the integrity 
of tight junctions [28]. Additionally, they observed decrease in inulin perm eability 
(a  marker of paracellular transport) and elevated levels of occludin. Experiments in 
mice with inactivated VDR gene confi rmed these fi ndings and showed that in these 
animals the healing of the corneal epithelium is impaired [36]. Th is indicates the 
important role of vitamin D in ma intaining the integrity of the cornea. Further studies 
on the positive eff ects of vitamin D on the barrier function of the corneal epithelium 
revealed that 1,25(OH)2D stimulates the migration of human corneal epithelial 
cells [37]. Interestingly, 24.25-dihydroxyvitamin D has the same  eff ect on the migration 
of these cells and also increases their proliferation [37]. However, experiments on 
mouse models in vivo and ex vi vo have s hown that topical calcitriol administration 
delays or completely inhibits wound healing in the cornea  [38,  39]. It may be the 
result of the calcitriol inhibitory eff ect on corneal epithelial proliferation [37].
Anti-angiogenic properties
Research conducted in order t o investigate 1,25(OH)2D eff ect on angiogenesis have 
proven that it acts as a  potent inhibitor of the angiogenic processes in vitro and in 
vivo [40]. Th e  question then arose whether calcitriol has the same e ff ect in the eye. 
In the experiment performed using the mouse model of oxygen-induced ischemic 
retinopathy, 1,25-dihydroxyvitamin D demonstrated the ability to inhibit retinal 
neoangiogenesis in a dose-dependent manner [41]. Although in vitro studies revealed 
that it suppresses endo thelial cell capillary morphogenesis, calcitriol was shown to 
have no infl uence on endothelial cell proliferation or migration at the concentrations 
observed to be minimally cytotoxic. Nevertheless, it inhibits the proliferation of 
pericytes in culture [31] what is consistent with the mentioned above VDR expression 
i n these cells.
Further research, conducted recently by Jamali et al., was focused on analyzing the 
mechanism of action by which vitamin D aff ects angiogenesis in the eye. Since VDR is 
associated with both genomic and rapid pathways it was hypothesized that it may play 
a  signifi cant role in the retinal vascular development and its inhibition by calcitriol. 
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First of all, it was discovered that the lack of VDR expression in mice, resulting in 
an increase in pericytes, impairs neovascularization but only at a  late stage  [31]. 
Secondly, the vitamin D receptor-defi cient mice were presente d to be resistant to the 
anti-angiogenic properties of 1,25(OH)2D during oxygen-induced retinopathy  [31]. 
These findings may suggest that VDR expression is relevant for the physiologic 
maturation of blood vessels and, what is more, for vitamin D anti-angiogenic activity 
in pathological conditions. 
In support of this hypothesis is evidence acquired from experiments on zebrafi sh 
which are an acclaimed model for studying embryonic vascular development. 
Calcitriol and 8 other VDR agonists were identifi ed as inhibitors of developmental 
angiogenesis in zebrafi sh larvae eye [42]. Th is anti-angiogenic eff ect of VDR agonists 
correlated with inc reased expression of dre-miR-21, which is one of the micro-RNAs 
involved in the regulation of cell proliferation, migration, and apoptosis. Surprisingly, 
a  recent study demonstrated that miR-21 is responsible for neovascularization 
and retinal inflammation in a  mouse model of diabetic retinopathy through 
down-regulation of PPARα [43]. Th ese results are in agreement with experiments 
which identifi ed  miR-21 as a promotor of pathological angiogenesis in the ischemic 
retina [44]. Activation of miR-21 has been shown to be dependent on the STAT3 
t ranscriptio n factor and results in signifi cantly decreased expression of the tissue 
inhibitor of the metalloproteinase gene (TIMP3). However, there is also evidence of 
miR-21 anti-angiogenic activity since it suppressed pathological vascular development 
in a mouse model of choroidal neovascularization [45].
Topical administration of 1,25(OH)2D has a  mild anti-angiogenic eff ect on 
corneal vessel formation as well. Scientists induced angiogenesis by sutures placed 
in the center of mouse cornea. Th e  neovascularization was suppressed in mouse 
cornea treated with vitamin D but only at the highest concentrations used in this 
experiment [46].
Anti-infl ammatory properties
It is now known that vitamin D is a  sig nifi cant modulator of innate and adaptive 
immune system, through VDR that is present in immune cells, and thus play an 
important role in the regulation of infl ammatory responses. As CYP27B1 is expressed 
in T cells, B cells and antigen presenting cells, vitamin D can be activated locally and 
act in an autocrine manner. Moreover, both VDR and 1-hydroxylase expression in 
macrophages increase aft er Toll-like receptors activation by pathogens [47]. 
In vivo study has shown that 1,25(OH)2D is able to inhibit corneal i nfl ammation 
by suppressing Langerhans cells migration into cornea [46]. In vitro calcitriol 
inhibits the production of IL-1α, IL-1β and IL-8 [ 48]. When researchers induced 
inflammation in human corneal epithelial cells by a  TLR3 agonist, simultaneous 
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treatment with vitamin D protected against excessive production of pro-infl ammatory 
mediators such as IL-1β, IL-6, IL-8, TNFα, and CCL20 [35]. However, this eff ect is 
observed only aft er co-treatment lasting longer than  6 hours or in cells pretreated for 
24 hours [49]. A more thorough analysis of the mechanism of this anti-infl ammatory 
response r evealed an increase in IκBα (nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, alpha) protein levels [49]. Similar results were obtained 
from experiments on the rat dry eye model induced by topical administration of 
benzalkonium chloride, in which 1,25(OH)2D attenuated inflammation [50]. In 
addition, studies of dry eye using human corneal epithelial cells under hyperosm otic 
conditions showed that calcitriol suppress also the expression of other chemokines 
(MIP1A and MIP1B) as well as activation of NF-κB [50]. In agreement with above 
mentioned findings regarding IκBα, it appears that vitamin D  influences NF-κB 
pathway. Moreover, activation of NF-κB is induced by TLR-signaling and it has been 
found that calcitriol down-regulates TLR3, TLR4 and TLR7 expression [50].
Likewise, vitamin D down-regulated the expression of the pro-inflammatory 
mediators (IL-1β and IL-8) in the culture of human corneal epithelial cells colonized 
with Pseudomonas Auerginosa [51]. Notably, corneal cells are more eff ective in killing 
bacte ria when treated with vitamin D [35]. Th is benefi cial eff ect on the surface of the 
eye may be due to the increased production of the antimicrobial peptide LL-37 [35]. 
By means of immunochemistry, the authors of another experime nt demonstrated 
that the fungal pathogen (Fusarium solani) increases the expression of VDR in 
corneal epithelial cells [52] and it is already known that the fungal antigens increase 
the  expression of TLR2 together with TLR4 and dectin-1 in these cells [53, 54]. 
Interestingly, treatment with Toll-like receptor 2 antibody inhibited this up-regulated 
expression suggesting the presence of TLR2-dependent VDR activation pathway. 
Vitamin D also appears to infl uence the effi  cacy of medication used to treat fungal 
keratitis. Calcitriol enhances the immunosuppressive function of cyclosporine, during 
A.fumigatus infection, in human corneal cells, while VDR inhibitor weakens it [55].
Th e vast number of reports indicate that vitamin D may infl uence the development 
and progression of autoimmune diseases [56]. It seems to be mainly the result of 
its inhibitory eff ect on the  diff erentiation of Th 17 and Th 1 cells [57]. In a model of 
autoimmune uveitis, calcitriol appears to suppress Th 17 response by aff ecting lineage 
commitment and production of IL-17 [58]. Th is ability of vitamin D to prevent and 
even partially reverse abn ormal immune response may be also due to its impact on 
the function of dendritic cells [57].
The  anti-inflammatory effect of vitamin D was also observed in the r etina. 
According to Lee et al., subcutaneous injections of calcitriol signifi cantly reduce 
the number of activated macrophages and attenuate chronic infl ammation in the 
mouse retina [59]. In the meantime, intraperitoneal administration of 1,25(OH)2D 
has bee n shown to reduce oxidative stress and inflammation in the lacrimal 
112 Kamil Skowron, Ilona Pawlicka, Krzysztof Gil
glands of radioiodine treated rats [60]. However, these results were based solely on 
histopathological and bioc hemical changes, regardless of their eff ect on the function 
of the lacrimal glands.
Diabetic Retinopathy
It can be hypothesized that due to its anti-angiogenic and anti-infl ammatory activity, 
vitamin D protects against the development of diabetic retinopathy. In 2012, a group 
of scientist found that 1,25(OH)2D is able to inhibit VEGF and TGF-β expression in 
the retinal tissues of diabetic rats [61]. Interestingly, recent fi ndings in this fi eld have 
reported that in a  rat  model of diabetic retinopathy, calcitriol has a  protective eff ect 
on the retinal structure, i.e. the number of cells in the ganglion cell layer and retinal 
thickness [62]. In addition, treatment with calcitriol was found to inhibit retinal cells 
 apoptosis and decrease retinal vascular permeability. Th is is the result of reducing the 
production of reactive oxygen species, thus blocking the TXNIP/NLRP3 pathway.
Age-related macular degeneration
Although the exact pathogenesis of AMD remains unclear, infl ammation, oxidative 
stress, and neoangiogenesis are thought to underlie this disease [63]. Th erefore, it has 
been suggested that vitamin D activity is a  factor that c an signifi cantly aff ect these 
pathogenic steps. As we know, VDR and the enzymes involved in the vitamin D 
metabolism are expressed both in the retina and choroid. It allows 1,25(OH)2D to 
act directly in the eye. In the mouse cone cells treated with H2O2 in order to induce 
oxidative stress, vitamin D has been shown to increase cell viability and reduce the 
production of reactive oxygen species [64]. In addition, it up-regulated the expression 
of antioxidant enzymes such as c atalase, superoxide dismutase, and glutathione 
peroxidase. Mice injected subcutaneously with vitamin D for 6 weeks showed not 
only a  reduction in retinitis but also a  lower accumulation of beta-amyloid, which 
is a  component of AMD-associated deposits [59]. Th is activity together with its 
ability to inhibit infl ammation and angiogene sis present vitamin D as a  potential 
protection against the development of AMD, but further investigation is necessary to 
confi rm this.
Retinoblastoma
Th ere is compelling evidence for the role of vitamin D in cancer growth and 
development. It has been found to have anticancer activity through regulation of 
apoptosis, angiogenesis, cell diff erentiation, proliferation, and migration [65]. As 
a  result, in vitro and in vivo calcitriol, as well as its analogs, inhibit  the growth of 
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various malignant tumors such as breast, colon or prostate cancer [66]. Some analogs 
are currently undergoing clinical trials as anti-cancer drugs [67].
Vitamin D receptor expression was detected in a  human retinoblastoma cell 
line ( Y-79), tumors from the transgenic mouse retinoblastoma model (LH beta-Tag 
tumors) and ultimately in human retinoblastoma samples [68]. Th e eff ect of calcitriol 
on these cells was then investigated. It was shown that  in vitro calcitriol inhibits 
the growth of Y-79 retinoblastoma cells [68, 69]. Subsequently, in vivo experiments 
were conducted. In athymic nude mice injecte d with Y-79 cells (xenograft  model) 
and LH beta-Tag mice (transgenic model) treatment with calcitriol or ergocalciferol 
led to a signifi cant reduction in tumor growth [68]. However, the doses required for 
this eff ect appeared to be highly toxic for the ani mals due to hypercalcemia. Th ere 
is a  retrospective study suggesting that the co-administration of calcitriol with 
a  saline solution reduces its toxicity, and hence mortality of animal models [70]. 
It is based mainly on the result of the experiment, in which it was proven that the 
 combination therapy with cisplatin and calcitriol is highly eff ective in the treatment 
of retinoblastoma xenograft model [71]. For 5 weeks, the authors of this study 
administered saline in addition to calcitriol  with cisplatin or calcitriol alone without 
any deaths in any of the groups. Another approach to reducing the mortality caused 
by vitamin D treatment is focused on its ana logs with less hypercalcemic activity. 
Synthetic analogs of calcitriol such as 1,25-dihydroxy-16-ene-23-yne-Vitamin D3 
(16,23-D3) and 1α-hydroxyvitamin D2 (1α-OH-D2) were tested. It has been proven 
that they inhibit the growth of relatively small tumors with less toxicity than 
calcitriol or ergocalciferol [68, 72, 73]. However, eff ective doses in the treatment of 
large tumors continued to cause hyp ercalcemia and increased mortality as a  fi nal 
complication [74]. In addition, 16,23-D3 proved ineff ective during prolonged use i.e. 
15 weeks [74]. Follow ing experiments investigated the eff ectiveness of another analog 
2-methylene-19-nor- (20S)-1-hydroxybishomopregnacalciferol (2MbisP). Finally, 
2MbisP has been shown to inhibit the growth of retinoblastoma without causing 
hypercalcemia or increased mortality [75].
1,25(OH)2D and its analogs exert anti-neoplastic activity by inducing tumor 
cell apoptosis  without aff ecting cell proliferation either in xenograft  or transgenic 
models. Based on immunostaining for p53 in the region of cell death, the activation 
of apoptosis by vitamin D analogs seems to be mediated by the tumor suppressor 
protein p53 [68, 76]. Consistent with the fact that the p53 suppressor gene regulates 
the expression of both a nti-apoptotic Bcl-2 protein and pro-apoptotic Bax  [77], 
calcitriol has been shown to increase Bax levels and reduce Bcl-2 in retinoblastoma 
cells [69 ]. Various authors have reported that programmed cell death induced by 
vitamin-D analogs is also  associated with an increase in p21 protein levels [68, 76]. 
Th e cyclin-dependent kinase inhibitor p21 may promote as well as inhibit apoptosis, 
either  through p53-dependent or p53-independent pathways [78], and therefore the 
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exact role of this protein requires more detailed studies. Inhibition of angio genesis 
appears to be a secondary mechanism responsible for this anti-tumor eff ect [79].
Conclusions
Numerous epidemiological studies have linked vitamin D defi ciency with ocular 
disease s such as myopia, age-related macular degeneration, diabetic retinopathy, 
glaucoma, retinoblastoma, and uveitis, but the underlying mechanism is not yet 
fully understood. However, recently discovered anti-angiogenic, anti-infl ammatory, 
and anti-neoplastic properties of calcitriol have shed some light on its role in the 
pathogenesis of ocular diseases. Vitamin D, through ubiquitously expressed receptors, 
appears to act as a  protective factor in the eye, where its local production and 
activation is possible due to the presence of required enzymes.
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